Free Trial
NASDAQ:PBYI

Puma Biotechnology (PBYI) Stock Price, News & Analysis

Puma Biotechnology logo
$3.08 -0.10 (-3.14%)
Closing price 05/1/2025 04:00 PM Eastern
Extended Trading
$3.08 0.00 (-0.16%)
As of 05/1/2025 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Puma Biotechnology Stock (NASDAQ:PBYI)

Key Stats

Today's Range
$3.06
$3.19
50-Day Range
$2.74
$3.62
52-Week Range
$2.23
$5.26
Volume
228,853 shs
Average Volume
442,043 shs
Market Capitalization
$152.80 million
P/E Ratio
6.42
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Buy

Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

PBYI MarketRank™: 

Puma Biotechnology scored higher than 76% of companies evaluated by MarketBeat, and ranked 177th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Puma Biotechnology has only been the subject of 1 research reports in the past 90 days.

  • Read more about Puma Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Puma Biotechnology is 6.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.76.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Puma Biotechnology is 6.42, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.51.

  • Price to Book Value per Share Ratio

    Puma Biotechnology has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Puma Biotechnology's valuation and earnings.
  • Percentage of Shares Shorted

    7.39% of the float of Puma Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Puma Biotechnology has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Puma Biotechnology has recently decreased by 0.35%, indicating that investor sentiment is improving.
  • Dividend Yield

    Puma Biotechnology does not currently pay a dividend.

  • Dividend Growth

    Puma Biotechnology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.39% of the float of Puma Biotechnology has been sold short.
  • Short Interest Ratio / Days to Cover

    Puma Biotechnology has a short interest ratio ("days to cover") of 7.7.
  • Change versus previous month

    Short interest in Puma Biotechnology has recently decreased by 0.35%, indicating that investor sentiment is improving.
  • News Sentiment

    Puma Biotechnology has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Puma Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Puma Biotechnology's insider trading history.
Receive PBYI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

PBYI Stock News Headlines

Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millions of years. And both grizzled oilmen and clean energy supporters love it: Energy Secretary Chris Wright called it "an awesome resource," while Warren Buffett, Jeff Bezos, Mark Zuckerberg, and Bill Gates are all directly invested.
See More Headlines

PBYI Stock Analysis - Frequently Asked Questions

Puma Biotechnology's stock was trading at $3.05 at the beginning of 2025. Since then, PBYI stock has increased by 1.0% and is now trading at $3.08.
View the best growth stocks for 2025 here
.

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its earnings results on Thursday, February, 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. The biopharmaceutical company earned $59.10 million during the quarter, compared to the consensus estimate of $52.50 million. Puma Biotechnology had a trailing twelve-month return on equity of 41.60% and a net margin of 9.56%.
Read the conference call transcript
.

Top institutional shareholders of Puma Biotechnology include Bank of New York Mellon Corp (0.69%), PFG Investments LLC (0.04%) and Patriot Financial Group Insurance Agency LLC (0.02%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Douglas M Hunt, Michael Patrick Miller and Troy Edward Wilson.
View institutional ownership trends
.

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA).

Company Calendar

Last Earnings
2/27/2025
Today
5/02/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PBYI
Employees
200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+127.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
6.42
Forward P/E Ratio
9.94
P/E Growth
N/A
Net Income
$21.59 million
Pretax Margin
10.13%

Debt

Sales & Book Value

Annual Sales
$230.47 million
Cash Flow
$0.74 per share
Price / Cash Flow
4.19
Book Value
$1.12 per share
Price / Book
2.75

Miscellaneous

Free Float
37,454,000
Market Cap
$152.80 million
Optionable
Optionable
Beta
1.34

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:PBYI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners